Rubicon Research IPO Subscription: Pharmaceutical Company’s Public Issue Booked Over 25 Times - Check GMP, Price Band And Other Details

Rubicon Research IPO Subscription: The initial public offering (IPO) of Rubicon Research is scheduled to close for subscription on October 13. The pharmaceutical company’s public issue opened for subscription on October 9.

The IPO has been booked over 25 times on the final day of subscription, at the time of writing. The grey market premium (GMP) of the pharma company’s shares also witnessed a slight decline on the third day of subscription.

Rubicon Research IPO: Subscription On Day 3

Rubicon Research IPO has received bids for over 418.71 million shares so far against the 16.40 million shares offered for subscription, leading to the issue being booked 25.45 times.

Non-institutional investors (NIIs) are leading the demand, as the issue has been booked over 58 times in the NII category. They have placed bids for 263.2 million shares of the company against the 4.47 million shares reserved for the category. Retail investors have booked the IPO 21.26 times so far. RIIs placed bids for 63.45 million shares compared to the 2.98 million shares set aside for them. Qualified institutional buyers (QIBs) have applied for 91.59 million shares of the public issue so far on the last day of bidding against the 8.95 million shares reserved for the category, booking the issue 10.23 times.

Employees of the company applied for 297,780 shares compared to the 42,168 shares offered for subscription, leading to the issue being booked 7.06 times so far.

Rubicon Research IPO GMP

The GMP of Rubicon Research IPO declined on the final day of bidding from Rs 110 per share to Rs 96 per share, according to several websites which track the demand for unlisted shares on the grey market. Rubicon Research shares are expected to list with gains of 19.70 per cent at Rs 581 per share.

Rubicon Research IPO Issue Size

Rubicon Research seeks to raise Rs 1,377.5 crore from its public issue. The pharma company’s issue size consists of a fresh issue of 10.30 million shares amounting to Rs 500 crore and an offer for sale (OFS) of 18.10 million shares aggregating to Rs 877.50 crore. The minimum lot size for retail individual investors was fixed at 30 shares, which aggregates to an investment of Rs 14,550.

Rubicon Research IPO: Subscription Dates and Listing Date

Rubicon Research IPO opened for subscription on October 9. Rubicon Research IPO subscription window is scheduled to close on October 13. The share allotment status of Rubicon Research IPO will be announced on October 14. Subsequently, Rubicon Research will issue refunds for unsuccessful applicants on October 15. Rubicon Research shares are scheduled to list on the bourses on October 16.

Rubicon Research: Financials

Rubicon Research posted a total income of Rs 356.95 crore in the June quarter of FY 2025-26. In the quarter under review the pharmaceutical firm’s net profit and net worth stood at Rs 43.3 crore and Rs 593.67 crore respectively.

In FY25 the company posted a total income of Rs 1,296.22, up by over 48 per cent from Rs 872.39 crore in the preceding fiscal. The pharma company’s net profit for FY25 stood at Rs 134.36 crore, up by 47 per cent from Rs 91.01 crore in the preceding fiscal. The net worth of the company surged by 40 per cent to Rs 540.98 crore in FY25 compared to Rs 385 crore in FY24.

Rubicon Research IPO: Registrar

Rubicon Research IPO’s book running lead manager is Axis Capital and the registrar for the issue is MUFG Intime India.

Rubicon Research: Promoters

The promoters of Rubicon Research include General Atlantic Singapore RR, Pratibha Pilgaonkar, Sudhir Dhirendra Pilgaonkar, Parag Suganchand Sancheti, Surabhi Parag Sancheti and Sumant Sudhir Pilgaonkar. Promoters of the pharmaceutical company held 77.67 per cent stake in the company prior to the public issue.

Rubicon Research IPO: Objective

Rubicon Research plans to use the funds generated by the pharmaceutical company for prepayment or scheduled repayment of its outstanding borrowings and for funding unidentified acquisitions and general corporate purposes.

About Rubicon Research

Rubicon Research manufactures differentiated pharmaceutical formulations. The pharma company’s portfolio includes 72 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products. The company markets over 350 stock-keeping units (SKUs) to 96 customers as of June 30, 2025.